Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been FiledJan 24, 2023
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private PlacementJan 11, 2023
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to FollowJan 10, 2023